




















































































Figure S1. Titration of TCR stimulation, related to Figure 1.
A. Naïve CD4+ T cells were stimulated with polystyrene beads coated with indicated amounts of αCD3 and 
1 µg/mL of αCD28 for 5 minutes. Mean fluorescence intensity (MFI) of phosphorylated ZAP70, SLP76 and 
ERK was measured by flow cytometry gating on bead-bound cells. B. MFI of ERK phosphorylation at 1 
µg/mL of αCD3 was measured from 0 to 60 minutes. C. Frequency of CD69+ cells were determined by 
flow cytometry after 16 hours of TCR stimulation with indicated αCD3 concentrations. Experiments shown 
are representative of four experiments.
Figure S2. Longitudinal epigenomic and transcriptomic changes induced by TCR stimulation
Naïve CD4+ T cells from eight individuals were stimulated with 0.01 (low, square) or 1 µg/mL (median, 
triangle) αCD3-coated beads and subjected to ATAC-seq and RNA-seq at indicated time points. A. Bar 
graphs show the number of peaks more or less accessible in activated cells compared to base line at each 
time point. B. Total differential peaks between low (left) or high (right) TCR stimulation and baseline are 
plotted as average log2 fold-change (logFC) versus log2 mean reads per peak. Peaks with p-values below 
0.05 are indicated in red. C. Bar graphs show the number of significantly up- or down-regulated gene 
transcripts for each time point (p < 0.05). D. Total up- or down-regulated gene transcripts in activated cells 
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Figure S3. Higher intensity TCR stimulation amplifies age-associated chromatin accessibility 
differences seen at baseline or with low intensity stimulation
Sites more accessible (p< 0.05) in naïve CD4+ T cells from young (left) or old (right) adults were identified 
at baseline and at several time points after TCR stimulation with beads coated with low and medium 






















Figure S4. related to Figure 2C. Activation-induced temporal patterns of epigenetic changes in 
naïve CD4+ T cells from young and older adults.
A. Peak sets in clusters with different temporal patterns and membership scores >0.6 as shown in Figure 
2C were analyzed for TF motif enrichments by HOMER. Graphs show the fold enrichment (X-axis) in each 
cluster from young (to the left) and old (to the right) adults plotted vs the significance level (Y-axis). Five 
TFs with the lowest p-values are shown. B. Genes assigned to differentially accessible regulatory sites 
were examined for significant enrichment in biological pathways. Selected GO terms associated with the 
different temporal patterns in young (upper panel) and older adults (lower panel) are shown. C.  Gene 
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 Figure S5, related to Figures 2D and E. Relationship between differential accessibility of 
regulatory regions and transcriptome
 A. Aggregate genome accessibility tracks of representative sites of cluster 7-10 shown in the heat plot 
in Figure 2D (left panel). Cyan-shaded areas indicate peaks that are more open in young (cyan) 
compared to older adults (magenta). Transcript data from corresponding genes as determined by 
RNA-seq (right panel). B. LogFC difference of transcripts differentially expressed between young and 
older adults from 48-hour RNA-seq data is plotted against logFC difference of differential peaks from 
ATAC-seq data annotated to the same gene at the indicated time point. Data are fitted with linear 
regression.  
Cluster 7: SYTL2 Cluster 8: BCL11A



















Figure S6, related to Figure 4. Single cell epigenetic and transcriptional analysis of naïve CD4+ 
T cell responses.
Nuclei pooled from unstimulated and activated naïve CD4+ T cells were subjected to scATAC- and 
scRNA-seq. Imputed CD69 gene expression is projected on the UMAP of scATAC-seq. Clusters of 
resting and activated cells were distinguished based on containing CD69-expressing cells (left panel). 
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Figure S7. Constitutive expression of the IL-2 receptor on naïve CD4+ T cells from older 
individuals.
A. Gating strategy for naïve CD4+ T cells. B. IL2RA gene expression was quantified in unstimulated 
naïve CD4+ T cells from 10 young and 12 older adults.  C. CD25 was stained on resting naïve CD4+ T 





























































Figure S8, related to Figure 5. IKZF2 binding to IL2RA enhancers from ENCODE ChIP-seq.
A. ATAC-seq genome tracks of unstimulated naïve CD4+ T cells from young and older adults were 
aligned with ENCODE ChIP-seq genome tracks of indicated TFs at IL2RA enhancer locus (see Figure 
5A). The location of enhancer A and enhancer B is indicated by red bars. B. IKZF2 and IL2RA 
transcripts from sorted CD25+ and CD25- naïve CD4+ T cells from 7 donors. 
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Figure S9, related to Figure 6. Genome accessibility changes induced by IL-2 receptor 
blocking.
A. LogFC of differential peaks between IL-2 receptor (IL-2R) blocking and PBS treatment (p<0.05) are 
plotted against average peak size. Peaks that are also differentially accessible between young and 
older individuals are indicated in dark red. B. Accessibility tracks of representative genes. Magenta 
shaded areas indicate peaks that are more open in older adults and with PBS treatment; cyan indicate 





































Supplement table 1. Study Population 
Subject Ethnicity Gender Age Enrolled experiment 
1 Caucasian M 25 TCR-stimulation time course 
2 Asian F 70 TCR-stimulation time course 
3 Caucasian M 71 TCR-stimulation time course 
4 Caucasian F 30 TCR-stimulation time course 
5 Asian F 32 TCR-stimulation time course 
6 Caucasian M 65 TCR-stimulation time course 
7 Caucasian M 29 TCR-stimulation time course 
8 Caucasian M 74 TCR-stimulation time course 
9 Caucasian F 35 scMultiome  
10 Asian M 34 scMultiome  
11 Caucasian F 79 scMultiome 
12 Caucasian M 69 scMultiome  
13 Caucasian M 78 STAT5 inhibition ATAC-seq  
14 Caucasian F 80 STAT5 inhibition ATAC-seq  
15 Caucasian M 78 STAT5 inhibition ATAC-seq  
16 Caucasian F 81 STAT5 inhibition ATAC-seq  
 




Antibody name Clone Supplier Catalog # Application 
Anti-CD69 BV605 FN50 BioLegend 310937 Surface staining 
Anti-CD25 BV421 BC96 BioLegend 302629 Surface staining 
Anti-CD3 PE-Cy7 UCHT1 BioLegend 300420 Surface staining 
Anti-CD4 AF700 RPA-T4 BioLegend 300526 Surface staining 
Anti-CD45RA AF750 HI100 BioLegend 304151 Surface staining 
Anti-CCR7 PerCP-Cy5.5 G043H7 BioLegend 353219 Surface staining 
Anti-ZAP70 pY319 AF647 17A/P-ZAP70 BD 557817 Phosflow 
Anti-SLP76 pY128 AF488 J141-668.36.58 BD 558439 Phosflow 
Anti-ERK pT202 PE-CF594 20A BD 562644 Phosflow 
Anti-TCF1 PE 7F11A10 BioLegend 65520725 TF staining 
 Anti-BLIMP1 APC 646702 R&D systems IC36081A TF staining 
Anti-IRF4 polyclonal Cell Signaling 4964 Western blot 
Anti-BHLHE40 Polyclonal Novus Bio NB100-1800 Western blot 
Anti-β-actin 13E5 Cell Signaling 4970 Western blot 
Anti-ERK pT202 D13.14.4E Cell Signaling 4370 Western blot 
Anti-LAT pY132 polyclonal Invitrogen 44-224 Western blot 
Anti-STAT5 pY694 polyclonal Cell Signaling 9351 Western blot and ChIP 
Anti-HELIOS D8W4X Cell Signaling 42427 Western blot and ChIP 
Anti-CD25 BC96 BioLegend 302602 IL-2 receptor blocking 
Anti-CD122 TU27 BioLegend 339002 IL-2 receptor blocking 
